HK Stock Market Move | MEITU (01357) opened nearly 6% higher, with an expected adjusted net profit attributable to parent company shareholders for last year to increase by approximately 60% to 66% year-on-year.
Meitu Inc. (01357) opened nearly 6% higher and, as of the time of writing, rose by 5.77% to 6.6 Hong Kong dollars, with a trading volume of 5.2173 million Hong Kong dollars.
MEITU (01357) opened nearly 6% higher, as of the time of drafting, it has risen by 5.77% to 6.6 Hong Kong dollars, with a turnover of 5.2173 million Hong Kong dollars.
In terms of news, on February 8, MEITU announced that, according to the group's preliminary evaluation, based on non-International Financial Reporting Standards, MEITU is expected to achieve a year-on-year increase of approximately 60% to 66% in adjusted profit attributable to equity holders of the parent company in 2025. The significant improvement in MEITU's profitability is mainly due to rapid growth in revenue from its core business of imaging and design products, driven primarily by the rapid increase in global paid subscription users. Among them, the growth rate of paid subscription users from international markets is higher than that of the Chinese mainland market. The board of directors believes that adjusted profit attributable to equity holders of the parent company can better reflect the company's core operating performance.
Related Articles

HK Stock Market Move | SINO BIOPHARM (01177) rose more than 3% with the completion of subject enrollment in Phase III clinical trial of Vituximab Bevacizumab "CLDN18.2 ADC".

HK Stock Market Move | JIAXIN INTL RES (03858) surges more than 6%, expected to turn loss into profit last year, with a maximum profit of up to HK$340 million.

BofA Securities: Maintains "Buy" rating on INNOVENT BIO (01801) with a target price of HK$113.5.
HK Stock Market Move | SINO BIOPHARM (01177) rose more than 3% with the completion of subject enrollment in Phase III clinical trial of Vituximab Bevacizumab "CLDN18.2 ADC".

HK Stock Market Move | JIAXIN INTL RES (03858) surges more than 6%, expected to turn loss into profit last year, with a maximum profit of up to HK$340 million.

BofA Securities: Maintains "Buy" rating on INNOVENT BIO (01801) with a target price of HK$113.5.

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


